Vanda Pharmaceuticals (VNDA) PT Raised to $24 at Brean Capital Following Fanapt Ruling

August 26, 2016 9:33 AM EDT
Get Alerts VNDA Hot Sheet
Price: $13.25 -2.57%

Rating Summary:
    8 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade VNDA Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Brean Capital analyst Difei Yang reiterated a Buy rating and raised his price target on Vanda Pharmaceuticals (NASDAQ: VNDA) to $24.00 (from $20.00).

This follows the favorable ruling on the '610 patent, which prevents the FDA approving ANDA to Fanapt until November, 2027 which is a major improvement from our previous assumption of generic entry in 2023.

For an analyst ratings summary and ratings history on Vanda Pharmaceuticals click here. For more ratings news on Vanda Pharmaceuticals click here.

Shares of Vanda Pharmaceuticals closed at $14.17 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Brean Capital

Add Your Comment